Evidence map›Paper›PMID 42851487›Full record

ArticleFrontiers in pharmacology2026

Targeting the AcrAB-TolC efflux pump by small molecules selectively addressing the outer membrane factor TolC.

Janis Veliks, Cristina D Cruz, Tania Szal, Marina Madre, Irena Leite, Laura Paunina, Philipp Lewe, Maren Hinz, Susanne Witt, Päivi Tammela and 2 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Janis Veliks *Latvian Institute of Organic Synthesis, Riga, Latvia.
Cristina D Cruz *Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Tania Szal *Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Hamburg, Germany.
Marina MadreLatvian Institute of Organic Synthesis, Riga, Latvia.
Irena LeiteLatvian Institute of Organic Synthesis, Riga, Latvia.
Laura PauninaLatvian Institute of Organic Synthesis, Riga, Latvia.
Philipp LeweCentre for Structural Systems Biology (CSSB), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Maren HinzCentre for Structural Systems Biology (CSSB), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Susanne WittCentre for Structural Systems Biology (CSSB), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Päivi TammelaDrug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Aigars JirgensonsLatvian Institute of Organic Synthesis, Riga, Latvia.
Björn WindshügelFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gram-negative bacteria express several efflux pump complexes extruding a broad spectrum of antibiotics. The major efflux pump in Methods: A virtual screening campaign was utilized to identify potential TolC binders. Virtual hits were investigated using a functional efflux assay, followed by synergy tests with piperacillin and determination of the intrinsic antibacterial potential. Bindings studies with individual efflux pump proteins were carried out. Synthetic chemistry was applied to improve the efficacy of the compound. Microbiological and biophysical tests were used to characterize the compounds with respect to synergistic activity with antibiotics and efflux pump binding. Results: We identified a small molecule interfering with efflux pump function, showing synergistic activity with piperacillin and binding to TolC which was further optimized at various positions. The most promising compounds revealed TolC-selective binding and shifted the minimum inhibitory concentration of piperacillin and levofloxacin at low micromolar concentrations. Conclusion: Our study provides evidence that TolC may represent a valid target for the development of an antibiotic adjuvant.

Indexed as

AcrAB-TolCantimicrobial resistanceE. coliefflux pumpsouter membrane factorTolC

Identifiers

PMID42851487
PMCPMC13645612

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.